Determination of skin concentrations of enrofloxacin in dogs with pyoderma

C. DeManuelle
Search for other papers by C. DeManuelle in
Current site
Google Scholar
PubMed
Close
 DVM
,
P. J. Ihrke
Search for other papers by P. J. Ihrke in
Current site
Google Scholar
PubMed
Close
 VMD
,
C. M. Brandt
Search for other papers by C. M. Brandt in
Current site
Google Scholar
PubMed
Close
 BS
,
P. H. Kass
Search for other papers by P. H. Kass in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
P. R. Vulliet
Search for other papers by P. R. Vulliet in
Current site
Google Scholar
PubMed
Close
 PhD, DVM

Click on author name to view affiliation information

Objective

To compare serum and skin concentrations of enrofloxacin in dogs with pyoderma with those of clinically normal dogs and to evaluate concentrations in dogs with superficial versus deep pyoderma.

Animals

16 clinically normal dogs and 16 dogs with pyoderma.

Procedure

Enrofloxacin (approx 5 mg/kg of body weight, PO) was administered daily to all dogs. Serum samples and skin biopsy specimens were obtained on day 1 at 3 hours after drug administration and on day 3 immediately before and 3 hours after drug administration. Samples and specimens were assayed by high-performance liquid chromatography. Morphometric analysis was performed on skin biopsy specimens to determine correlation between inflammatory cells and peak tissue enrofloxacin concentration on day 1.

Results

Morphometric analysis revealed high correlation between dermal inflammatory cell count and drug concentration in dogs with pyoderma.

Conclusions

At mean dosage of 5 mg/kg once daily, enrofloxacin tissue concentrations were significantly greater in dogs with pyoderma at 3 hours after pill administration. Enrofloxacin tissue concentration on day 3 at 3 hours after pill administration was 12.4 times the 90% minimum inhibitory concentration of enrofloxacin for Staphylococcus intermedius.

Clinical Relevance

In dogs with pyoderma, therapeutic tissue concentrations of enrofloxacin are reached as early as 3 hours after drug administration. (Am J Vet Res 1998;59:veterinary medicine-veterinary medicine)

Objective

To compare serum and skin concentrations of enrofloxacin in dogs with pyoderma with those of clinically normal dogs and to evaluate concentrations in dogs with superficial versus deep pyoderma.

Animals

16 clinically normal dogs and 16 dogs with pyoderma.

Procedure

Enrofloxacin (approx 5 mg/kg of body weight, PO) was administered daily to all dogs. Serum samples and skin biopsy specimens were obtained on day 1 at 3 hours after drug administration and on day 3 immediately before and 3 hours after drug administration. Samples and specimens were assayed by high-performance liquid chromatography. Morphometric analysis was performed on skin biopsy specimens to determine correlation between inflammatory cells and peak tissue enrofloxacin concentration on day 1.

Results

Morphometric analysis revealed high correlation between dermal inflammatory cell count and drug concentration in dogs with pyoderma.

Conclusions

At mean dosage of 5 mg/kg once daily, enrofloxacin tissue concentrations were significantly greater in dogs with pyoderma at 3 hours after pill administration. Enrofloxacin tissue concentration on day 3 at 3 hours after pill administration was 12.4 times the 90% minimum inhibitory concentration of enrofloxacin for Staphylococcus intermedius.

Clinical Relevance

In dogs with pyoderma, therapeutic tissue concentrations of enrofloxacin are reached as early as 3 hours after drug administration. (Am J Vet Res 1998;59:veterinary medicine-veterinary medicine)

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 439 439 103
PDF Downloads 35 35 2
Advertisement